Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Animal Virus Infections Studies, and vaccines and immunoinformatics approaches.
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
Gene Editing of Primary Rhesus Macaque B Cells
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
Evolution of antibody immunity to SARS-CoV-2
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Replication and single-cycle delivery of SARS-CoV-2 replicons
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients